Hemato-biochemical changes during xylazine-ketamine and xylazine-thiopentone anesthesia in dogs

Background: This study was conducted to evaluate certain haemato-biochemical changes during Xylazine-Ketamine (X-K) and Xylazine-Thiopentone (X-T) anesthesia in dogs. Methods: For this, six dogs of 18 to 25 kg BW were selected and divided into two groups: Group I (X-K) and Group II (X-T). Atropine sulfate @ 0.05 mg/kg BW (IM) was used for premedication in both groups. Dogs in Group I (n=3) were anaesthetized with Xylazine HCl @ 1.1 mg/kg BW (IM) and Ketamine HCl @ 5.5 mg/kg BW (IM), whereas Xylazine HCl @ 1.1mg/kg BW (IM) and Thiopentone sodium @ 20 mg/kg BW (IV) were used for anesthesia in Group II (n=3). In both groups, peripheral blood samples were collected from the dogs before induction of anesthetic agents (control) and thereafter on 10, 20, 30, and 40 minutes of post-induction and again after complete recovery from anesthesia to evaluate hematological changes in Total Erythrocyte Count (TEC), Haemoglobin (Hb) and Packed Cell Volume (PCV). In addition, serum biochemical changes in Total Serum Protein (TSP), Blood Urea Nitrogen (BUN), Creatinine, Sodium (Na), Potassium (K), and Chloride (Cl) were also assessed in both groups. Results: TEC, Hb, and PCV were altered significantly (P<0.05) in most of the cases, TSP was decreased significantly (P<0.05) but BUN was increased significantly (P<0.05), and creatinine was also increased in both groups during the experiment. There were mild alterations in Na, K, and Cl values after induction, and found near to the baseline (control) after recovery. Conclusions: These findings ascertained that the anesthetic combinations of X-K and X-T assert some definite haemato-biochemical changes in dogs which should be carefully judged by the veterinarians during surgical interventions to avoid anesthesia-related risks and complications.

Hospital-prepared Low-dose Atropine Eye Drops for Myopia Progression Control using Atropine Sulfate Injection Diluted in Normal Saline and Lubricants

BackgroundAs commercial low-dose atropine eye-drops for myopia progression control are available in some countries, in-house preparation by diluting the 0.1% atropine eye-drop with sterile water or normal saline has been a common practice. Atropine injection is readily available and could be a more feasible alternative.ObjectiveTo assess the properties of the in-house low-dose atropine eye-drops prepared by diluting the atropine injection in two solvents and tested in two temperature conditions.MethodThe 0.01% atropine eye-drops (15ml) were prepared by diluting atropine sulfate injection with normal saline and lubricant eye-drops and stored at room temperature and in a refrigerator. All samples were daily dropped for 12 weeks to mimic real-life use, one of which was assessed every two weeks for the biological contamination and chemical properties. The active substance was compared with freshly prepared samples at the 12th week.ResultsThe 0.01% atropine eye-drops contains no bacteria, fungi, or particulate matter. The levels of atropine sulfate on all samples were comparable to the freshly prepared samples at the 12th week, regardless of the solvents used or storage conditions.ConclusionThe low-dose atropine eye-drops prepared from readily available atropine sulfate injection at healthcare facilities could be alternative to commercial products.